Atherosclerosis is an inflammatory disease resulting in the hardening and thickening of the wall of arteries and the formation of plaques, which comprise immune cells, mesenchymal cells, lipids, and extracellular matrix. The source of mesenchymal cells in the atherosclerotic plaques has been under scrutiny for years. Current endothelial-lineage tracing studies indicate that the endothelium is a source for plaque-associated mesenchymal cells. Endothelial cells can acquire a mesenchymal phenotype through endothelial-mesenchymal transition (EndMT), wherein the expression of endothelial markers and functions is lost and the expression of mesenchymal cell marker and functions acquired. Furthermore, EndMT can result in delamination and migration of endothelial cell-derived mesenchymal cells into the underlying tissue. Here, we review the contribution of EndMT in vascular disease focusing on atherosclerosis and describe the major biochemical and biomechanical signalling pathways in EndMT during atherosclerosis progression. Furthermore, we address how the well-established systemic atherosclerosis risk factors might facilitate EndMT during atherosclerosis.
Introduction
Atherosclerosis is a leading cause of death and morbidity. Atherosclerosis is an inflammatory disease resulting in the hardening and thickening of the wall of arteries and the formation of plaques. Atherosclerotic plaques are characterized by the accumulation of immune cells, smooth muscle cells (SMC) and (myo)fibroblasts, lipids, and extracellular matrix (ECM) in the artery wall. Unstable atherosclerotic plaques can rupture resulting in thrombosis and interruption of the blood flow. Despite the systemic nature of atherosclerotic risk factors-which comprise amongst others hypertension, diabetes mellitus (hyperglycaemia), obesity, dyslipidaemia, hyperhomocystinuria, and male gender-atherosclerotic lesions develop preferentially at vessel curvatures, branching points and bifurcations, where the blood flow is disturbed. 1, 2 This suggests the importance of haemodynamic forces in the initiation of the disease. Endothelial dysfunction plays a critical role in the development of atherosclerosis. 3, 4 The endothelium is the cell layer lining the luminal surface of the blood vessels and, in healthy individuals, is a major regulator of vascular homeostasis. 5 The main function of the endothelium is to form a barrier controlling the passage of molecules and cells from the bloodstream to the vessel wall and vice versa. Additionally, the endothelium responds to a series of chemical and biomechanical cues by secreting factors regulating vascular tone, SMC proliferation and migration, immune cell adhesion, thromboresistance, and vessel inflammation. 6 Most atherosclerotic risk factors can activate the endothelium, resulting in the expression of chemokines and cytokines (e.g. IL1, IL6, IL8, MCP-1) and adhesion molecules (e.g. VCAM-1, ICAM-1, E-selectin) that attract and facilitate immune cell extravasation. 5 Critical to the activation of endothelial cells (ECs) is the switch from nitric oxide (NO) signalling to reactive oxygen species (ROS) signalling. NO promotes homeostasis and maintains the vascular wall in a quiescent state by the inhibition of proinflammatory cytokine secretion, immune cell extravasation, SMC proliferation, thrombosis and by preventing vascular leakage, 3 whereas ROS induces NFjB signalling, the main regulator of inflammation. This state of oxidative stress is a common underlying mechanism for EC dysfunction in response to (biochemical and biomechanical) hypertension, 17 and cancer. 18 Recently, the contribution of EndMT to atherosclerosis development was established. [19] [20] [21] [22] In this review, we discuss the contribution of EndMT in vascular disease focusing on atherosclerosis and describe the major biochemical and biomechanical signalling pathways in EndMT during atherosclerosis progression. Furthermore, we address how the well-established atherosclerosis risk factors might facilitate EndMT during atherosclerosis.
Endothelial plasticity as origin of mesenchymal cells in atherosclerotic plaques
Plaque formation in atherosclerosis is associated with the accumulation of mesenchymal cells [i.e. vascular SMC, and (myo)fibroblasts] in the intima of the artery. These mesenchymal cells are critical in the progression of atherosclerosis as they secrete proinflammatory molecules and synthetize ECM proteins and metalloproteases which facilitate plaque build-up and regulate plaque stability. 23 The origins of the neointimal mesenchymal cells in the plaque have been under scrutiny for decades but have remained elusive. Under pathological conditions, SMC originating from the media 24 and fibroblasts from the adventitia 25 migrate, proliferate, and participate to the neointima thickening. Also, bone marrow-derived cells contribute to neointima formation under pathological conditions. 26 Recent observations in human, porcine, and mouse plaques suggest a substantial endothelial origin for neointimal mesenchymal cells, which express both endothelial (e.g. PECAM-1, Endocan, and VE-cadherin) and mesenchymal markers [e.g. aSMA, Notch3, Snail, SM22a, fibroblast-associated protein (FAP), FSP1 (S100A4), and Vimentin]. [19] [20] [21] [22] 22 These observations suggest that EndMT occurs in normal vascular homeostasis, albeit to a lesser extent than in atherosclerosis. Corroboratively, in healthy arteries, a proportion of EC express both endothelial markers and the EndMT-related transcription factors Snail, Twist1, and Gata4. 20, 27 However, the role of EndMT in the context of physiological vascular turnover warrants further investigation. Assessing the full extent of EndMT in vivo is challenged by (i) the lack of specific fibroblast markers (e.g. vimentin is a marker of activated EC and fibroblasts 28 ), (ii) the potential loss of endothelial marker expression by EC at the end of the transition, and (iii) the heterogeneity of EndMTderived cell populations. 22 Moreover, (iv) the classical endothelial markers (e.g. CD31, Tie-2) are also expressed by monocytes 29 which
can also express markers of the mesenchyme. 30 Caution must thus be taken when double immunofluorescence is used to analyse EndMT as the lack of cell-specific markers can underlie overinterpretation of the data. Thus, the use of a large panel of markers in combination is crucial to assess the full extent of EndMT and to better characterize the contribution of the resultant cells to plaque composition. In summary, several independent studies have revealed the prevalence of EndMT in atherosclerosis. [19] [20] [21] [22] Although the contribution of EndMT to disease initiation and progression requires further scrutiny, the extent of EndMT observed in the human plaque strongly correlates with the severity of the disease, implying clinical relevance of the EndMT process. 21, 22 EndMT may consist of multi-step fate changes, most likely regulated in differential and sequential manners, capable of giving rise to mesenchymal cells in the plaque. Understanding this multi-step process as well as a better characterization of the resultant cells are of great interest in order to control the EC fate and be able to eradicate the emergence of potential detrimental cell populations.
Biochemical signals in EndMT
The discovery that EndMT is an active contributor to pathologies such as atherosclerosis and fibrosis has intensified research into the molecular mechanisms that drive EndMT. In this section, we discuss the biochemical signals that induce EndMT, modulate its progression and the currently identified endogenous inhibitors of EndMT. Snail1 is present in luminal EC overlying human coronary artery plaques, and Gata4, Twist1, and Snail1 are all expressed in luminal EC in atheroprone areas of the mouse aorta. 20, 27 At these sites, Gata4 regulates Twist1 expression, which in turn induces Snail1 in EC. 27 The upstream regulators as well as the downstream targets of this pathway are still unclear, but might include TGF-b, 32 Notch, 31 and Wnt 35 signalling ( Figure 2) . Endothelial-specific deletion of Gata4 or Twist1 reduces lesion size in atherosclerotic mice, suggesting that the Gata4-Twist1-Snail1 pathway contributes to atherosclerosis. As these TF are critical regulators of EndMT (Figure 2 ), understanding their regulations and downstream targets in the vascular endothelium is of great interest to understand the molecular basis controlling EndMT in atherosclerosis.
TGF-b and EndMT
Canonical TGF-b signalling is considered the driving force of EndMT. 36 TGF-b1 is the prototypic member of a large family of growth factors that includes the activins and bone morphogenetic proteins (BMPs 41 Conflicting data exist on the necessity of TGF-b1 for embryonic EndMT. Singleknockout mutant mice lacking TGF-b1 are born without cardiac malformations, 42 ,43 yet a subset of TGF-b1 -/-mice develop multiple cardiac malformations, resulting in embryonic lethality. 42 In atherosclerosis, all TGF-b isoforms are expressed, but with a marked spatial and cellular variability. 44, 45 In vitro, TGF-b2 appears to have a higher efficacy for the induction of EndMT; 38 however, data exploring the distinct and overlapping functions of the TGF-b isoforms in EndMT induction and progression during adult pathology are lacking. Thus, during atherosclerosis development, EndMT might be induced by multiple TGF-b isoforms and further detailed molecular and quantitative studies are necessary to elucidate this conundrum.
In EC, activin-like kinases (ALK) 1 and ALK5 are the predominant type I TGF-b receptors. 46 The binding of TGF-b to ALK1 activates, i.e. phosphorylates, the R-SMADs SMAD1 and SMAD5, which promote vascular homeostasis, EC proliferation, and angiogenesis. 47, 48 In contrast, binding of TGF-b to ALK5 induces the activation of the R-SMADs SMAD2 and SMAD3, which inhibit EC proliferation and facilitate EndMT. 48, 49 Interestingly, activation of ALK1 by TGF-b antagonizes the ALK5 activity, 46, 48 which might explain the pleiotropic responses of the EC to Besides, PKC-d activity promotes the activity of protein phosphatase 2a (PP2A), 56 resulting in the dephosphorylation of occludins and their subsequent loss from the tight junctions. 57 Indeed, blocking PP2A signalling with neutralizing peptides reduces EndMT; 58 (iii) RhoA, 59 which results in the expression of genes encoding cytoskeletal proteins as well as the reorganization of the cytoskeletal structure. 59, 60 RhoA activation triggers multiple downstream cellular events, including the nuclear accumulation of the myocardin-related transcription factors, 61 which facilitate the expression of cytoskeletal genes (e.g. transgelin, aSMA, and calponin) and the transcription factor Slug, 60 facilitating EndMT.
TGF-b signalling is more complex than solely receptor-ligand binding and subsequent biochemical signalling. First, all TGF-b isoforms are secreted as inactive precursors containing a C-terminal peptide that renders the TGF-bs inactive. This latency-associated peptide (LAP) needs to be enzymatically removed from TGF-b before signalling can commence. 62 Secondly, within the ECM, multiple matrix-associated proteins such as betaglycan (also known as TGF-b Receptor 3) bind the secreted TGF-b and act as reservoir for the pericellular storage of TGFb. 63 Thirdly, even when the LAP is removed, within the ECM, the association of TGF-b with the latent TGF-b-binding proteins (LTBP) renders TGF-b inactive, until mechanical forces disrupt the TGF-b-LTBP complex and liberate TGF-b from this inactivation. 64 Finally, endoglin, a type III TGF-b receptor, directs the actions of TGF-b in ECs by favouring ALK1 signalling and blunting ALK5-SMAD2/3 activation, 65 which suggests that high endoglin expression might inhibit EndMT initiation or progression. Future in-depth molecular investigations are necessary to elucidate the enigma of the contribution of TGF-b-binding proteins on the regulation of EndMT during atherosclerosis development and progression. Thus, TGF-b signalling via ALK5 induces a series of canonical and noncanonical signalling cascades that induce expression of the EndMT transcriptional programme. In coronary artery disease patients, the extend of EndMT (as revealed by Notch3 expression) and the extend of TGF-b activation (as revealed by the presence of activated SMAD2) are strongly associated in the luminal endothelium, 21 which suggest that endothelial TGF-b activity participates to plaque progression by stimulating EndMT. 68, 69 Notch can directly activate Twist1 expression 70 and facilitates the recruitment of SMAD3 to SMAD-binding elements in the promoters of a variety of mesenchymal genes, 71 including Slug. 31 Additionally, Jagged-1-induced activation of Notch signalling results in the nuclear accumulation of the mesenchymal transcription factor RUNX3 that induces the expression of several mesenchymal genes. 72, 73 Wnt/b-catenin signalling is essential for EndMT during heart valve development. 74, 75 The inhibition of GSK3b by Wnt/b-catenin results in the stabilization of Snail and thus increased EndMT; 50, 76 however, Wnt/ b-catenin signalling might also induce EndMT in a direct manner. Indeed, Wnt3a induces the expression of transgelin 77 and other mesenchymal proteins in EC, 35 which can be inhibited by the Wnt-inhibitor DKK1. 78 Contrastingly, signalling through Wnt7a inhibits EndMT. 79 These conflicting data indicate that further studies are necessary to conclusively establish the role of Wnt-signalling in EndMT. Currently, a role for Notch and Wnt signalling in EndMT during atherosclerosis has not been established. In summary, EndMT can be induced by a variety of signalling mechanisms, both canonical and non-canonical. How these mechanisms crosscommunicate, or whether there is a hierarchical order between these mechanisms remains elusive. Yet, the high number of pathways resulting in EndMT suggests that EndMT plays a major role in normal physiology, which might become aberrant or aggravated during disease.
Modulation of EndMT by disease pathways: hypoxia, inflammation, and oxidative stress
Atherosclerotic plaques are characterized by an increase in inflammatory signalling, hypoxia, and oxidative stress. 22 Hypoxia aggravates EndMT by facilitating the nuclear accumulation of SMAD2/3. 80 Hypoxia-inducible factor (HIF)-1a is the archetype sensory protein for oxygen. HIF-1a is constitutively expressed in EC, but degraded under normoxic conditions. HIF-1a degradation is regulated by oxygen sensors that constitutively direct HIF-1a towards the proteasomal degradation route. During hypoxia, HIF-1a degradation is inhibited, resulting in its nuclear accumulation. 81 Interestingly, Snail, Twist1, and ALK5 are transcriptional targets of HIF-1a, [82] [83] [84] which might explain the increased sensitivity of EC to TGF-b signalling under hypoxic conditions. Indeed, pharmacological inhibition of HIF-1a reduces ALK5 expression and abolishes EndMT. 82 It must be noted that the contribution of hypoxia to EndMT of luminal ECs is contradictory as atherosclerosis development is not associated with a decrease in pO 2 . However, the proportion of ECs that delaminate and migrate into the underlying neointima during EndMT might encounter tissue hypoxia and this hypoxia might aggravate the EndMT process. Inflammatory signalling synergizes with TGF-b in the induction of EndMT 38, 85 and inflammatory stress exacerbates atherosclerosis progression in mice. 86 Proinflammatory cytokines (e.g. IL-1b and TNFa) activate the transcription factor NFjB, resulting in elevated expression of TGF-b1 and TGF-b2, 38,54 the main inducer of EndMT. Besides the convergence of inflammation with TGF-b signalling, proinflammatory cytokines might also induce EndMT in a TGF-b-independent manner. 85, 87 This inflammation-induced EndMT relies on the induction of Snail by NFjB (Figure 2) , 88,89 a major transcriptional regulators of
EndMT. The exact pathway of inflammation-induced EndMT has yet to be elucidated and how it converges with or diverges from canonical TGF-b-induced EndMT needs to be further investigated. TGF-b induces oxidative stress in EC through the induction of mitochondrial dysfunction, 52 resulting in the activation of NFjB (Figure 2 ).
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As stated previously, elevated levels of endothelial oxidative stress and NFjB activity increase the expression of TGF-b1 and TGF-b2 and consequently EndMT. 38, 54 Moreover, oxidative stress can activate latent TGF-b in a number of ways; (i) oxidation of the LAP, 90, 91 and (ii) matrixmetalloproteinase (MMP)-mediated degradation of LAP. 92 The reduction of oxidative stress by exogenous antioxidants reduces endothelial oxidative stress and consequently EndMT. 93 Interestingly, MMP-9, a TGF-b activating MMP, facilitates EndMT in kidney fibrosis, indicative of a role for oxidative stress responses in mesenchymal transition. 94 Together, these data imply that inflammation, hypoxia, and oxidative stress in the endothelium aggravate EndMT by the induction of canonical TGF-b signalling.
Endogenous inhibitors of EndMT: fibroblast growth factor signalling and ALK5 antagonism
In contrast to the factors that induce EndMT, endogenous factors that inhibit EndMT have received only limited attention. Fibroblast growth factor (FGF) signalling might be the best characterized endogenous inhibitor of EndMT. FGF signalling in EC induces the expression of several microRNAs that decrease the expression of ALK5 (Figure 2) .
66,67
Moreover, FGF signalling directly antagonizes the ALK5-induced expression of mesenchymal genes in a Ras/MEK1-dependent manner. 95 Disruption of FGF signalling by EC-specific deletion of the FGF receptor 1 (FGFR1) 96 or FGF Receptor Substrate 2a 21 aggravates EndMT and the progression of atherosclerosis, 21, 96 whereas restoration of FGF receptor signalling inhibits EndMT in diabetic nephropathy. 97 Endothelial signalling through BMP-7 reduces EndMT (Figure 2) , albeit through unidentified mechanisms. 13, 98 Endogenous antagonists of ALK5 signalling, such as ALK1 agonists in EC, might block the induction of EndMT through a variety of mechanisms, namely (i) the induced expression of inhibitory Smads that prevent the phosphorylation of Smad2/3 99 and thereby EndMT, 100 and (ii) the ALK1-induced expression of inhibitor of DNA binding (ID) proteins ( Figure 2) . 46, 48 ID proteins are dominant negative helix-loop-helix proteins that lack a DNA-binding domain. ID proteins heterodimerize with other transcription factors, resulting in the formation of non-functional complexes. 101 Interestingly, EndMT is associated with decreased expression of ID proteins, 11 and restoration of ID protein expression reverts EMT of certain epithelial tumours. 102 These data suggest a regulatory role for endogenous ALK1 ligands in the regulation of EndMT; however, data are currently unavailable.
EndMT in atherosclerosis
In summary, EndMT has emerged as a pathological process that can be induced by multiple signalling cascades (i.e. TGF-b, Notch, and Wnt/ b-catenin). Moreover, the transcriptional regulation of EndMT, primarily regulated by Snail, Slug, and Twist, is facilitated by hypoxia, inflammation, and oxidative stress. Research into endogenous antagonists of the EndMT programme is in its infancy, yet FGF signalling is identified as a potent inhibitor of EndMT and the atherosclerotic process. 21 ,96
Focal risk factors and EndMT in atherosclerosis
Biomechanical forces such as shear stress and (cyclic) wall strain play an important role in vascular development, homeostasis, and the pathology of several cardiovascular conditions including atherosclerosis. 103, 104 In this section, we focus on how mechanical forces can influence EndMT and contribute to atherosclerosis.
EndMT and shear stress in atherosclerosis
EC are extremely sensitive to shear stress, the frictional force exerted by the blood flow oriented tangential to the EC. EC sense shear stress through a large variety of mechanosensory complexes which convert the mechanical stimuli into biochemical signals (reviewed in Ref. 105) . Disturbed blood flow, characterized by low and oscillatory shear stress (LOSS) occurring at the branching point and curvatures, induces plaque initiation, whereas high uniform shear stress (HSS) is atheroprotective. [106] [107] [108] Snail, Twist1, and Gata4 are expressed in the endothelium at sites of LOSS in healthy murine aorta 20, 27 and mesenchymal markers have been detected in the luminal EC exposed to disturbed flow in the porcine abdominal aortic trifurcation. 19 Concurrently, a combination of signalling pathways favourable to EndMT is present in low shear stress area: FGFR1 expression is decreased in EC by LOSS at atheroprone regions, whereas TGF-b is activated, 21 suggesting that LOSS is an activating signal for EndMT. Indeed, the imposition of LOSS on carotid arteries in healthy animals triggers the expression of EndMT transcription factors in EC 20, 27 and aortic constriction-induced LOSS causes co-expression of endothelial and mesenchymal markers. 19 These data imply that LOSS induces
EndMT possibly by regulating the balance between FGF and TGF-b signalling and by activating Gata4-Twist1-Snail pathway. LOSS induces ROS production and inflammatory signalling, 103, 109 which both favour EndMT during atherosclerosis ( Figure 3) . LOSS enhances oxidative stress in EC by the production of ROS. 52, 110 High levels of ROS in EC cause a change in morphology and the induction of EndMT markers with the concurrent down-regulation of endothelial gene expression, 22 suggestive of EndMT induction by LOSS-derived oxidative stress. LOSS increases vascular inflammation and enhances EC proliferation, apoptosis, and senescence, thereby increasing vascular permeability and contributing to atherosclerosis development.
111-113 LOSS-induced
EndMT may contribute to these alterations of EC function. Moreover, LOSS recruits monocytes to the endothelium and promotes the differentiation of M1-type foam cell which secrete CCL4, IL-1b, and TNFa. CCL4 can induce EndMT by increasing endogenous TGF-b expression in ECs, 114 suggesting that the interplay between ECs and foam cells is of importance to EndMT induction during atherosclerosis.
EndMT has been linked to an increased vascular inflammation as TAK1, Twist1, and Gata4 promote the endothelial expression of inflammatory molecules (i.e. VCAM-1 and ICAM-1) under LOSS conditions. 27, 52 In turn, inflammatory signalling promotes EndMT in an NFjB-dependent pathway, 38, 87 thus establishing a positive feedback loop. In addition, Twist1, Gata4, and Snail have all been shown to promote EC proliferation and permeability under LOSS conditions. 20, 27 In contrast to the areas of LOSS, EndMT does not occur in HSS regions of the vasculature, suggesting a protective effect of HSS. [19] [20] [21] HSS inhibits EndMT via activation of the MEK5/ERK5 pathway and KLF4 transcription factors, 19, 115 which can inhibit Snail expression ( Figure 3) . 116 Interestingly, HSS-induced activity of KLF transcription factors induces the expression of the inhibitory Smad7, 117 thereby directly antagonizing the EndMT programme. Additionally, HSS stabilizes EC junction by controlling VE-cadherin localization at the membrane through Rac/Rho signalling ( Figure 3) . 118, 119 Loss of adherent junctions is an initiating feature of EndMT. In summary, it has become apparent that LOSS induces EndMT in atheroprone regions; however, the precise mechanisms linking wall shear stress and the activation of EndMT need further elucidation. On the contrary, HSS is a powerful inhibitor of EndMT via activation of protective ERK5/KLF pathway. Further work is now required to determine at which extend LOSS-induced EndMT contributes to EC dysfunction leading to focal atherosclerosis and to define the underlying mechanisms.
EndMT and cyclic strain
Cyclic strain (CS) is the blood pressure-derived force causing a repetitive deformation of the artery wall in the circumferential direction perpendicular to the EC as a result of the pulsatile blood flow. The physiological level of CS is around 10% in the human aorta, but this can vary highly during aging 120 (1.5-4%) or when the wall of the aorta becomes stiffer due to diseases such as hypertension (>10%). 121 Mechanical stretch induces the expression of SMC markers in EC. 122, 123 Pathological strain induces the expression of TGF-b and BMPs in ECs and drives cardiac valve calcification via EndMT. 124, 125 Depending on the strain magnitude, different signalling pathways are activated that can induce EndMT. TGF-b is activated under a relatively low strain (10%), whereas b-catenin/Wnt signalling is increased at high pathological strains (15-20%) ( Figure 3) . 124 Corroboratively, endothelial TGF-b expression is elevated by hypertension, 126 a condition associated with pathological CS. These data suggest that CS might contribute to the activation of TGF-b signalling during atherosclerosis. Physiological levels of CS increase the migration and proliferation of EC while inhibiting apoptosis via PI3-kinase-mediated activation of Akt, 127, 128 whereas elevated levels of CS (>15%) induce the expression of metalloproteases (MMPs) in ECs, such as MMP-1, MMP-2, and MMP-9. 128, 129 Interestingly, MMP-9 expression by ECs activates the EndMT transcriptional programme through Notch signalling, 94 suggesting that elevated levels of CS in atherosclerosis 130 might aggravate EndMT.
The small GTPases Rac and Rho regulate junctional stability of EC in a CS-dependent manner, 131, 132 wherein junctional stability is dependent on the membranous localization of VE-cadherin. 133 Physiological CS (5%) favours Rac activation, whereas pathological CS (>15%) suppresses Rac activity and enhances Rho-mediated signalling, 131 thereby causing the internalization of VE-cadherin and dissociation of endothelial adherens junctions, 134 initiating EndMT.
Pathological CS induces mitochondrial ROS release and the subsequent activation of NFjB signalling. 135 The resulting state of oxidative stress and inflammation facilitates EndMT by enhancing the expression of TGF-b and the activation of its signalling through ALK5. 54 In summary, EC homeostasis is highly dependent on CS, wherein at physiological levels homeostasis is maintained and at pathological levels multiple EndMT-inducing signalling cascades are activated. Therefore, it is highly likely the interplay between EC and CS contributes to the focal development of atherosclerosis.
Matrix stiffness and EndMT
Vascular stiffening accompanies several cardiovascular conditions, such as hypertension 136 and atherosclerosis. 137 Arterial stiffening results from ECM remodelling within the vessel wall, characterized by degradation of elastin in the ECM and deposition and cross-linking of collagen molecules, 138 and occurs as a result of aging, diabetes, renal disorders, and atherosclerosis.
EC sense matrix stiffness through focal adhesions. 139 Focal adhesions are adhesion plaques, primarily formed by integrins complexes that act as an interface between the actin cytoskeleton and ECM, transmitting mechanical forces across the cell membrane. Matrix stiffness influences a variety of cell functions including proliferation, differentiation, migration, and apoptosis. [140] [141] [142] [143] Vessel stiffness promotes the adaptation of an atherogenic phenotype in EC, 144 ,145 yet little is known about how arterial stiffness affects ECs within blood vessels where arteriosclerosis initiates. High matrix stiffening promotes the activation of RhoA, 146 a regulator of Slug-induced EndMT 60 and nuclear translocation of Twist1. 147 Matrix stiffness also regulates Yes-associated protein (YAP) and the transcriptional coactivator with PDZ-binding motif (Taz) signalling pathway potentially through activation of integrins. 148 YAP/Taz signalling collaborates with Snail and Slug to induce the mesenchymal transcription factor Runx2. 149 Moreover, increasing matrix of SMAD2 and EndMT. 21 Together, these data suggest an important role for YAP/Taz signalling in EndMT and atherosclerosis development, resulting in a vicious circle of increasing vessel stiffness and atherosclerosis progression. 153 
Systemic risk factors and EndMT in atherosclerosis
In the sections above, we have reviewed the biochemical and biomechanical factors that mediate EndMT at atheroprone sites. In the following section, we explore the mechanisms by which systemic atherosclerosis risk factors might induce or facilitate EndMT. Ang-II, 165 drastically reduces fibrogenesis, EndMT, and atherosclerosis progression.
Hypertension and hyperglycaemia
In diabetes, the non-enzymatic reaction between glucose and serum proteins result in increased levels of advanced glycation end products (AGEs) that are biologically active and accumulate in the artery wall. 166 Binding of AGEs to their receptor (RAGE) initiates signalling event that induce or aggravate EndMT in diabetes, 167, 168 primarily through the NOX-induced activation of PKC 169 and subsequent increase in TGF-b expression. 170 
Obesity, dyslipidaemia, and EndMT
Obesity and atherosclerosis are characterized by dyslipidaemia, including the increase in serum oxidized low-density lipoprotein (oxLDL) levels. Increased oxLDL signalling might induce EndMT through a variety of cascades all including oxidative stress. 171, 172 OxLDL binding to its receptor LDLR induces signalling via PKC which increased endothelial MMP production in an oxidative stress-dependent manner. 173 Elevated levels of PKC signalling and MMP activity might increase endogenous TGF-b production 174 and activation, 92 and thus facilitate EndMT. 178 Of note, high-density lipoprotein (HDL), an established inhibitor of oxLDL signalling in EC, 179 abolished EndMT induction by yet unknown mechanisms. 180 
Hyperhomocystinuria and EndMT
Elevation of plasma homocysteine level is a risk factor for cardiovascular disease, including atherosclerosis. 181 Hyperhomocystinuria induces ER stress and a decrease in the production of the gasotransmitter H 2 S. 182 Interestingly, exogenous H 2 S supplementation protects against EndMT by the attenuation of ER stress and the resulting TGF-b signalling, 93 potentially through the activation of AMPK signalling, 182 resulting in the expression of inhibitory Smad-7. 183 
Oestrogen receptor signalling and EndMT
Atherosclerosis preferentially develops in male subjects, which might indicate a role for oestrogen signalling in atheroprotection 184 and the inhibition of EndMT. Indeed, in EMT, oestrogen signalling through its receptors ERa and ERb maintains the epithelial phenotype by the direct repression of Slug expression and loss of oestrogen signalling induces EMT. 185 In ECs, oestrogen signalling induces endothelial adherens and tight junction formation. 186 These data suggest that oestrogen might be an inhibitor of EndMT, yet, this hypothesis remains to be investigated. In summary, atherosclerosis risk factors can facilitate EndMT via multiple signalling cascades, all involving oxidative stress-induced expression and the activation of TGF-b signalling. Antagonizing the deranged signalling associated with atherosclerosis risk factors might inhibit EndMT and atherosclerosis progression.
Summary and conclusions
Atherosclerosis is a progressive pathological remodelling of the vessel wall, characterized by the accumulation of lipids and intimal mesenchymal cells, resulting in the creation of an atheromatous plaque. It is wellestablished that endothelial dysfunction plays a pivotal initiating role in atherosclerosis development. 187 Recent studies indicate another role for the endothelium in atherosclerosis development and progression that links the atherosclerosis initiating events to the subsequent vascular remodelling, i.e. EndMT. [19] [20] [21] EndMT is a process wherein the EC lose the expression of their characteristic marker proteins and cellular functions and acquire the expression of mesenchymal marker proteins and adopt mesenchymal cell functions, such as ECM production and contractile behaviour, thus adding to the pool of mesenchymal cells in the neointima. Here, we have reviewed the major biochemical and biomechanical signalling cascades that induce, modulate, or inhibit EndMT. It should be emphasized that, for clarity reasons, the biochemical signalling and biomechanical signalling cascades were discussed as separate entities; however, in combination they form an intricate signalling network in vivo. 188, 189 It becomes apparent that the native vessel architecture determines the areas at risk for atherosclerosis development through biomechanical signalling, either induced by LOSS or CS. 96, 153 At these so-called atheroprone areas, biochemical signals originating from the systemic atherosclerosis risk factors (e.g. inflammation, hyperglycaemia, and dyslipidaemia) induce endothelial dysfunction 5 and, if persistent, start to induce EndMT which participates in intimal hyperplasia. 19, 21 Vascular remodelling, originating from the increase in mesenchymal cells in the intima, results in an increase in vessel stiffness and cyclic wall strain, which might aggravate EndMT creating the vicious cycle that facilitates the progressive nature of atherosclerosis. Endothelial lineage tracing studies have established the occurrence of EndMT during atherosclerosis. 21, 96 Albeit that EndMT is implicated in atherosclerosis progression in humans, 22 the extent by which EndMT contributes to the initiation and progression of atherosclerosis needs further elucidation to provide a strong basis for anti-atherosclerosis therapies that specifically target EndMT. Although the endothelialspecific deletion of Erk5, an MAPK that protects against EndMT, 19 aggravates atherosclerosis development and pharmacological activation of Erk5 diminished atherosclerosis formation, 190 it is currently unknown whether the modulation of EndMT or the modulation of other antiatherosclerosis genes (i.e. KLF2, KLF4, and eNOS) underlies these observations. Concurrently, pharmacological activation of FGF signalling protects against EndMT-mediated atherosclerosis progression. 21, 97 Although these data are encouraging, proof-of-concept studies wherein EndMT is therapeutically targeted in advanced stages of atherosclerosis are missing. In summary, EndMT contributes to the initiation and progression of atherosclerosis. EndMT is modulated by multiple integrative pathways,
Box 1 Evidence suggesting a link between EndMT and atherosclerosis
• Endothelial-specific lineage tracing experiments showed contribution of endothelial-derived cells to atherosclerotic lesions.
• Expression of EndMT TF (Twist1, Snail, and Gata4) and activity of the potent EndMT inducer TGF-b (revealed by expression of p-Smad2) observed in luminal EC at atheroprone sites in healthy mice.
• TGF-b activity detected in the luminal endothelium overlying the plaque in human.
• Occurrence of EndMT in atherosclerotic plaque in mouse and human as suggested by co-expression of endothelial markers with EndMT TF or mesenchymal markers.
• Correlation between EndMT extent and plaque stability/disease severity in coronary artery disease patient.
• Hypoxia, oxidative stress, and inflammatory cytokines, all present in atherosclerotic plaque, constitute a favourable environment for EndMT • EC-specific deletion of main EndMT TF, i.e. Twist1 or Gata4 reduces the lesion size in atherosclerotic mice.
• EC-specific disruption of FGF signalling (known inhibitor of EndMT) leads to an increase of atherosclerotic development.
